Literature DB >> 25501304

Inhibition of mesothelioma cancer stem-like cells with adenovirus-mediated NK4 gene therapy.

Xu-Bin Deng1, Li Xiao2, Yue Wu1, Fang Jin2, Brooke Mossman3, Joseph R Testa2, Guang-Hui Xiao1,2.   

Abstract

Malignant mesothelioma (MM) is a highly invasive and chemoresistant malignancy induced by asbestos fibers. NK4, a hepatocyte growth factor antagonist and angiogenesis inhibitor, consists of the N-terminal hairpin domain and four kringle domains of the α-chain of hepatocyte growth factor. The therapeutic potential of NK4 has been demonstrated in a variety of tumor types. However, the mechanisms by which NK4 inhibits tumor growth have not been well delineated. In this study, it is shown that the NK4 adenovirus (Ad-NK4) potently inhibits cell viability, invasiveness and tumorigenicity of human MM cells. Significantly, this study demonstrates for the first time that Ad-NK4 inhibits cancer stem-like cell (CSC) properties as assessed by spheroid formation assay, side population analysis and flow cytometric sorting of CD24 cells. In addition to inhibiting phosphorylation of Met and AKT, Ad-NK4 markedly suppressed the active form of β-catenin, a key mediator of both Wnt and AKT pathways. It is further demonstrated that expression of NK4 suppresses β-catenin nuclear localization and transcriptional activity. Intriguingly, the expression levels of Oct4 and Myc, two critical stem cell factors and downstream targets of β-catenin, were also diminished by Ad-NK4. Furthermore, the strong antitumor effect of NK4 was found to be linked to its ability to inhibit CSCs as revealed by immunohistochemical examination of tumor specimens from a mouse xenograft model of human MM. These findings suggest that NK4 acts as a CSC inhibitor by impeding Met/AKT/β-catenin signaling and holds promise for achieving durable therapeutic responses in MM by constraining the CSC component of these aggressive tumors.
© 2014 UICC.

Entities:  

Keywords:  HGF/Met; NK4; cancer stem-like cells; malignant mesothelioma; therapy

Mesh:

Substances:

Year:  2014        PMID: 25501304      PMCID: PMC4428975          DOI: 10.1002/ijc.29391

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  49 in total

1.  In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells.

Authors:  Gabriela Dontu; Wissam M Abdallah; Jessica M Foley; Kyle W Jackson; Michael F Clarke; Mari J Kawamura; Max S Wicha
Journal:  Genes Dev       Date:  2003-05-15       Impact factor: 11.361

Review 2.  Malignant pleural mesothelioma.

Authors:  Harvey I Pass; Nicholas Vogelzang; Steven Hahn; Michele Carbone
Journal:  Curr Probl Cancer       Date:  2004 May-Jun       Impact factor: 3.187

3.  Core transcriptional regulatory circuitry in human embryonic stem cells.

Authors:  Laurie A Boyer; Tong Ihn Lee; Megan F Cole; Sarah E Johnstone; Stuart S Levine; Jacob P Zucker; Matthew G Guenther; Roshan M Kumar; Heather L Murray; Richard G Jenner; David K Gifford; Douglas A Melton; Rudolf Jaenisch; Richard A Young
Journal:  Cell       Date:  2005-09-23       Impact factor: 41.582

Review 4.  Multimodality treatments in the management of malignant pleural mesothelioma: an update.

Authors:  Raphael Bueno
Journal:  Hematol Oncol Clin North Am       Date:  2005-12       Impact factor: 3.722

5.  Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties.

Authors:  Dario Ponti; Aurora Costa; Nadia Zaffaroni; Graziella Pratesi; Giovanna Petrangolini; Danila Coradini; Silvana Pilotti; Marco A Pierotti; Maria Grazia Daidone
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

Review 6.  Mechanisms and significance of bifunctional NK4 in cancer treatment.

Authors:  Kunio Matsumoto; Toshikazu Nakamura
Journal:  Biochem Biophys Res Commun       Date:  2005-07-29       Impact factor: 3.575

Review 7.  Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma.

Authors:  Daniel H Sterman; Steven M Albelda
Journal:  Respirology       Date:  2005-06       Impact factor: 6.424

8.  Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth.

Authors:  Deborah A Altomare; Huihong You; Guang-Hui Xiao; Maria E Ramos-Nino; Kristine L Skele; Assunta De Rienzo; Suresh C Jhanwar; Brooke T Mossman; Agnes B Kane; Joseph R Testa
Journal:  Oncogene       Date:  2005-09-08       Impact factor: 9.867

Review 9.  Tumour-cell invasion and migration: diversity and escape mechanisms.

Authors:  Peter Friedl; Katarina Wolf
Journal:  Nat Rev Cancer       Date:  2003-05       Impact factor: 60.716

10.  HGF/NK4 inhibited VEGF-induced angiogenesis in in vitro cultured endothelial cells and in vivo rabbit model.

Authors:  M Nakabayashi; R Morishita; H Nakagami; K Kuba; K Matsumoto; T Nakamura; Y Tano; Y Kaneda
Journal:  Diabetologia       Date:  2002-12-06       Impact factor: 10.122

View more
  5 in total

1.  The role of MALAT1/miR-1/slug axis on radioresistance in nasopharyngeal carcinoma.

Authors:  Chuan Jin; Bingchuan Yan; Qin Lu; Yanmin Lin; Lei Ma
Journal:  Tumour Biol       Date:  2015-10-20

2.  Antiproliferation activities of NK4 on multiple myeloma.

Authors:  Wenzhong Que; Huili Liu; Qinqin Yang; Shanghua Xu
Journal:  Exp Ther Med       Date:  2018-08-22       Impact factor: 2.447

3.  Effect of Spheroidal Age on Sorafenib Diffusivity and Toxicity in a 3D HepG2 Spheroid Model.

Authors:  Christoph Eilenberger; Mario Rothbauer; Eva-Kathrin Ehmoser; Peter Ertl; Seta Küpcü
Journal:  Sci Rep       Date:  2019-03-19       Impact factor: 4.379

4.  NK4 Regulates Laryngeal Squamous Cell Carcinoma Cell Properties and Inhibits Tumorigenicity by Modulating the DKK1/Wnt/β-Catenin Axis.

Authors:  Shoukai Zhang; Hulai Wei; Xiaoqin Ha; Yueyu Zhang; Yufen Guo
Journal:  Front Oncol       Date:  2021-12-14       Impact factor: 6.244

5.  Preparation, Characterization, and in vivo Evaluation of NK4-Conjugated Hydroxycamptothecin-Loaded Liposomes.

Authors:  Ting Zhou; Wei Zhang; Dongliang Cheng; Xin Tang; Jianfang Feng; Wei Wu
Journal:  Int J Nanomedicine       Date:  2020-03-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.